Remy Gebleux

Title: Remy Gebleux: Innovator in Antibody Drug Conjugates

Introduction

Remy Gebleux is a notable inventor based in Basel, Switzerland. She has made significant contributions to the field of biotechnology, particularly in the development of antibody drug conjugates (ADCs). With a total of two patents to her name, her work focuses on improving the tolerability of these innovative therapies.

Latest Patents

Remy Gebleux's latest patents include "Anthracycline-based antibody drug conjugates having high in vivo tolerability." This invention relates to ADCs that present improved properties of in vivo tolerability, which is crucial for enhancing patient outcomes in cancer treatment. The advancements in her patents reflect her commitment to developing safer and more effective therapeutic options.

Career Highlights

Remy is currently employed at NBE-Therapeutics AG, where she continues to push the boundaries of research in antibody drug conjugates. Her work at this company has positioned her as a key player in the biotechnology sector, contributing to the advancement of cancer therapies.

Collaborations

Throughout her career, Remy has collaborated with esteemed colleagues such as Ulf Grawunder and Roger Renzo Beerli. These partnerships have fostered a collaborative environment that enhances innovation and research in the field.

Conclusion

Remy Gebleux is a pioneering inventor whose work in antibody drug conjugates is making a significant impact in the biotechnology industry. Her dedication to improving drug tolerability is paving the way for advancements in cancer treatment.